Amgen’s New Enbrel Patent May Undercut Health Care Plan

The extra patent protection of the profitable drug Enbrel, a rheumatoid arthritis and psoriasis treatment, could keep a cheaper version off the market until 2028.

Original - http://feeds.nytimes.com/click.phdo?i=69e11e6c519c1db4a4d5d1b14db1fbb5